AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21551479 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 150
Study 18296556 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg oral granules
Number of subjects: 12
Study 18296556 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 8 mg once daily for 7 days
Number of subjects: 12
Study 18296556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 18296556 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast 4 mg once daily for 7 days
Number of subjects: 12
Study 16575620 — intervention group
Group type: COMPARATOR
Intervention: Conventional operation with monopolar electrocautery and handsewn anastomosis (Group 1)
Number of subjects: 58
Study 16575620 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic scalpel and circular stapler (Group 2)
Number of subjects: 58
Study 16575620 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 58
Study 14739625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin alone
Number of subjects: 320
Study 14739625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin combined with heparin
Number of subjects: 320
Study 14739625 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin combined with heparin and ultrasound
Number of subjects: 320
Study 14739625 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptifibatide combined with aspirin, heparin, and ultrasound
Number of subjects: 320
Study 14739625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tirofiban combined with aspirin, heparin, and ultrasound
Number of subjects: 320
Study 10958091 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 microg x kg(‐1) oral clonidine
Number of subjects: 43
Study 10958091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 8769388 — intervention group
Group type: COMPARATOR
Intervention: Octreotide 100 micrograms subcutaneously three times daily for 3 to 6 weeks before surgery (group 1)
Number of subjects: 172
Study 8769388 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms subcutaneously three times daily for 3 to 9 months (group 2)
Number of subjects: 172
Study 8769388 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide 500 micrograms subcutaneously three times daily (increased dose for incomplete suppression in group 2)
Number of subjects: 172
Study 8446671 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 1 mg/kg body weight
Number of subjects: 300
Study 8446671 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 2 mg/kg body weight
Number of subjects: 300
Study 8446671 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 3 mg/kg body weight
Number of subjects: 300
Study 8446671 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine citrate 4 mg/kg body weight
Number of subjects: 300
Study 8446671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 8446671 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (any dose)
Number of subjects: 300
Study 2946644 — intervention group
Group type: EXPERIMENTAL
Intervention: Procaterol (20 mcg)
Number of subjects: 12
Study 2946644 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (200 mcg)
Number of subjects: 12
Study 2946644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 29261442 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT plus docetaxel
Number of subjects: 719
Study 29261442 — intervention group
Group type: COMPARATOR
Intervention: ADT alone
Number of subjects: 719
Study 29261442 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 719
Study 27585671 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 602
Study 27585671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 602
Study 25218600 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine (20 mg/d after 1 month of titration)
Number of subjects: 63
Study 25218600 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 22778120 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based training program for screening, diagnosis, and management of postpartum depression
Number of subjects: 2343
Study 22778120 — intervention group
Group type: COMPARATOR
Intervention: Usual care (30-minute presentation about postpartum depression)
Number of subjects: 2343
Study 19888921 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg (2.5 mg for <6 years)
Number of subjects: 49
Study 19888921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 18716362 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelnidipine (AZ) 16 mg/d
Number of subjects: 38
Study 18716362 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine-CR (NF) 40 mg/d
Number of subjects: 38
Study 15729174 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) added to regimen after withdrawal of cyclosporine A (CsA)
Number of subjects: 122
Study 15729174 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine A (CsA) continued
Number of subjects: 122
Study 12775230 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE (transcatheter arterial chemoembolization)
Number of subjects: 136
Study 12775230 — intervention group
Group type: COMPARATOR
Intervention: Non-TACE group (control)
Number of subjects: 136
Study 10321327 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcoholics with polyneuropathy
Number of subjects: 34
Study 10321327 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcoholics with spasticity
Number of subjects: 34
Study 10321327 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic alcoholics with polyneuropathy without spasticity
Number of subjects: 34
Study 10321327 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (controls)
Number of subjects: 34
Study 9173440 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 15-3 levels in breast cancer patients
Number of subjects: 430
Study 9173440 — intervention group
Group type: EXPERIMENTAL
Intervention: CA 15-3 test
Number of subjects: 430
Study 1836066 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist isradipine
Number of subjects: 18
Study 1836066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 6580439 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints at 4.42 mm (Group II)
Number of subjects: 75
Study 6580439 — intervention group
Group type: EXPERIMENTAL
Intervention: Occlusal splints at 8.15 mm (Group III)
Number of subjects: 75
Study 6580439 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splints at 1 mm (Group I)
Number of subjects: 75
Study 30230375 — intervention group
Group type: EXPERIMENTAL
Intervention: Flash-free adhesive (APC Flash‐Free Adhesive, 3M Unitek)
Number of subjects: 45
Study 30230375 — intervention group
Group type: COMPARATOR
Intervention: Conventional adhesive (APCII Adhesive, 3M Unitek)
Number of subjects: 45
Study 28668229 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral dose of probiotics for three weeks or until they gave birth
Number of subjects: 34
Study 28668229 — intervention group
Group type: COMPARATOR
Intervention: Standard antenatal care
Number of subjects: 34
Study 27118297 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual hyperinflation delivered by nurses
Number of subjects: 33
Study 23180751 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation
Number of subjects: 100
Study 23180751 — intervention group
Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy
Number of subjects: 100
Study 22040616 — intervention group
Group type: EXPERIMENTAL
Intervention: Faxed referral program
Number of subjects: 0
Study 22040616 — intervention group
Group type: COMPARATOR
Intervention: Control group (quit advice and printed information)
Number of subjects: 0
Study 19436282 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (spherical carbon adsorbent) 2-g sachets, oral, thrice a day for 4 weeks
Number of subjects: 20
Study 19436282 — intervention group
Group type: EXPERIMENTAL
Intervention: AST-120 (spherical carbon adsorbent)
Number of subjects: 20
Study 17370490 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Hegu (LI 4) and Sanyinjiao (SP 6) simultaneously
Number of subjects: 90
Study 17370490 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture at Hegu (LI 4) and Sanyinjiao (SP 6) successively
Number of subjects: 90
Study 17370490 — intervention group
Group type: COMPARATOR
Intervention: Control group treated with medicine
Number of subjects: 90
Study 15505150 — intervention group
Group type: EXPERIMENTAL
Intervention: AVP-923 (30 mg of DM plus 30 mg of Q) given twice daily for 28 days
Number of subjects: 140
Study 15505150 — intervention group
Group type: COMPARATOR
Intervention: DM (dextromethorphan hydrobromide)
Number of subjects: 140
Study 15505150 — intervention group
Group type: COMPARATOR
Intervention: Q (quinidine sulfate)
Number of subjects: 140
Study 11218745 — intervention group
Group type: EXPERIMENTAL
Intervention: Super-high-flow injection method (Group A)
Number of subjects: 200
Study 11218745 — intervention group
Group type: COMPARATOR
Intervention: Conventional injection method (Group B)
Number of subjects: 200
Study 9684799 — intervention group
Group type: EXPERIMENTAL
Intervention: TFPI
Number of subjects: 400
Study 9684799 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein C
Number of subjects: 400
Study 9684799 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammation-sensitive proteins, lipids, and coagulation factors
Number of subjects: 400
Study 7826654 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (WBC) intermittently every 15 min; clamp time range: 50-140 min
Number of subjects: 76
Study 7826654 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia (CBC) intermittently every 15 min; clamp time range: 50-140 min
Number of subjects: 76
Study 7826654 — intervention group
Group type: EXPERIMENTAL
Intervention: Warm blood cardioplegia (WBC) intermittently every 15 min
Number of subjects: 76
Study 3413910 — intervention group
Group type: EXPERIMENTAL
Intervention: Twenty-four-hour catheterization perioperatively
Number of subjects: 77
Study 3413910 — intervention group
Group type: COMPARATOR
Intervention: Straight catheterization postoperatively in the recovery room
Number of subjects: 77
Study 29880036 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose computed tomography screening
Number of subjects: 0
Study 29880036 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 27842707 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 0.2 mg.kg-1 followed by infusion at a rate of 2 mg.kg-1.h-1
Number of subjects: 30
Study 27842707 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine continuous infusion at 0.5 mg.kg-1.h-1
Number of subjects: 30
Study 26147842 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercise group
Number of subjects: 206
Study 26147842 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 206
Study 24237777 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-OCA tissue adhesive
Number of subjects: 29
Study 24237777 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular sutures
Number of subjects: 29
Study 21128827 — intervention group
Group type: EXPERIMENTAL
Intervention: Cheonggukjang (CH) 20g/day
Number of subjects: 45
Study 21128827 — intervention group
Group type: EXPERIMENTAL
Intervention: Red ginseng cheonggukjang (RGCH) 20g/day
Number of subjects: 45
Study 21128827 — intervention group
Group type: COMPARATOR
Intervention: Control (starch 2g/day)
Number of subjects: 45
Study 19925721 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time sleep facilitating cereal (225 mg tryptophan, 5.3 mg adenosine‐5'‐P, 6.3 mg uridine‐5'‐P per 100 g)
Number of subjects: 30
Study 19925721 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time sleep facilitating cereal with standard formula milk
Number of subjects: 30
Study 19925721 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time sleep facilitating cereal with enriched night milk (480 mg tryptophan, 8.8 mg uridine‐5'‐P, 7.6 mg adenosine‐5'‐P per 100 g)
Number of subjects: 30
Study 19925721 — intervention group
Group type: COMPARATOR
Intervention: Standard cereal (75 mg tryptophan/100 g product without nucleotides)
Number of subjects: 30
Study 16516851 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytes stimulated with A23187+PMA for 1 day
Number of subjects: 0
Study 16516851 — intervention group
Group type: EXPERIMENTAL
Intervention: Monocytes from volunteers with -137G/G genotype
Number of subjects: 0
Study 14579088 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-HMPAO SPET
Number of subjects: 84
Study 14579088 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-ECD SPET
Number of subjects: 84
Study 11938804 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenning Mixture (SNM)
Number of subjects: 100
Study 11938804 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (Control)
Number of subjects: 100
Study 9346455 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered previsit questionnaire
Number of subjects: 201
Study 8456141 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobilization and extension (experimental group, n = 14)
Number of subjects: 24
Study 8456141 — intervention group
Group type: COMPARATOR
Intervention: Flexion exercise regimen (comparison group, n = 10)
Number of subjects: 24
Study 3942667 — intervention group
Group type: EXPERIMENTAL
Intervention: General anaesthesia plus extradural blockade (Bupivacaine)
Number of subjects: 10
Study 3942667 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia (Control)
Number of subjects: 10
Study 31611612 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective neck dissection (END)
Number of subjects: 250
Study 29680419 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Bright Light Therapy (∼507 nm) and Sedentary Activity (sitting, watching TV)
Number of subjects: 60
Study 29680419 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Bright Light Therapy (∼507 nm) and Morning Activity (standing, playing motion-sensing videogame)
Number of subjects: 60
Study 29680419 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Light Therapy (∼643 nm) and Sedentary Activity (sitting, watching TV)
Number of subjects: 60
Study 29680419 — intervention group
Group type: EXPERIMENTAL
Intervention: Red Light Therapy (∼643 nm) and Morning Activity
Number of subjects: 60
Study 29680419 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups combined
Number of subjects: 60
Study 24997005 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA-rich oil capsules
Number of subjects: 94
Study 24997005 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA-rich oil capsules
Number of subjects: 94
Study 22424078 — intervention group
Group type: EXPERIMENTAL
Intervention: WEB (telepsychiatry)
Number of subjects: 167
Study 20547037 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 1294
Study 20547037 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1294
Study 17057418 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital admission
Number of subjects: 50
Study 17057418 — intervention group
Group type: COMPARATOR
Intervention: Outpatient assessment
Number of subjects: 50
Study 16450852 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment
Number of subjects: 0
Study 16450852 — intervention group
Group type: EXPERIMENTAL
Intervention: Reference treatment
Number of subjects: 0
Study 16450852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12413779 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle interventions (diet change and increased physical activity)
Number of subjects: 284
Study 12413779 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus exercise interventions
Number of subjects: 284
Study 9535150 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic blood pressure reading of 140 mmHg or more before 20 weeks' gestation
Number of subjects: 212
Study 9535150 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index, platelet angiotensin II binding site density, urinary calcium:creatinine ratio measured before 20 weeks gestation
Number of subjects: 212
Study 9535150 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure measurements at 28 weeks of pregnancy
Number of subjects: 212
Study 9535150 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma angiotensinogen concentration at 28 weeks of pregnancy
Number of subjects: 212
Study 9535150 — intervention group
Group type: EXPERIMENTAL
Intervention: Transient, presumed 'white-coat', systolic hypertension at the first pregnancy visit
Number of subjects: 212
Study 7632131 — intervention group
Group type: EXPERIMENTAL
Intervention: Current-modulated electrical stimulation through the medial collateral ligament (MCL)
Number of subjects: 11
Study 7632131 — intervention group
Group type: EXPERIMENTAL
Intervention: Current-modulated electrical stimulation through the lateral collateral ligament (LCL)
Number of subjects: 11
Study 2173168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (1 x 1.500 aPTT units plus 2 x placebo injections)
Number of subjects: 166
Study 2173168 — intervention group
Group type: COMPARATOR
Intervention: Low dose conventional heparin (3 x 5.000 IU)
Number of subjects: 166
Study 2173168 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 166
Study 2173168 — intervention group
Group type: COMPARATOR
Intervention: Low dose conventional heparin
Number of subjects: 166
Study 699483 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (30 mg) injected intravenously during uterine contractions (Group I)
Number of subjects: 33
Study 699483 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (30 mg) injected intravenously in the relaxation period (Group II)
Number of subjects: 33
Study 30739558 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential strategy (LV5FU2 followed by FOLFOX6)
Number of subjects: 407
Study 30739558 — intervention group
Group type: COMPARATOR
Intervention: Combination strategy (FOLFOX6 followed by FOLFIRI)
Number of subjects: 407
Study 27696793 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumates@Work internet-based program supplemented with 4 group sessions
Number of subjects: 49
Study 27696793 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 26390700 — intervention group
Group type: EXPERIMENTAL
Intervention: 252Cf neutron brachytherapy (700‐800 cGy doses at point A, once a week)
Number of subjects: 32
Study 26390700 — intervention group
Group type: COMPARATOR
Intervention: Neoadjuvant intra‐arterial embolism chemotherapy (bleomycin, carboplatin, and cyclophosphamide, twice)
Number of subjects: 32
Study 23164313 — intervention group
Group type: EXPERIMENTAL
Intervention: Large neutral amino acid (LNAA) supplementation
Number of subjects: 10
Study 23164313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 22151296 — intervention group
Group type: EXPERIMENTAL
Intervention: NVA237 50 μg once daily
Number of subjects: 822
Study 22151296 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 822
Study 18584897 — intervention group
Group type: EXPERIMENTAL
Intervention: CPC (circulating progenitor cells)
Number of subjects: 28
Study 18584897 — intervention group
Group type: COMPARATOR
Intervention: Inactive serum (control)
Number of subjects: 28
Study 17374034 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX)
Number of subjects: 215
Study 17374034 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study 15713722 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg nandrolone decanoate
Number of subjects: 54
Study 15713722 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg nandrolone decanoate
Number of subjects: 54
Study 15713722 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg nandrolone decanoate
Number of subjects: 54
Study 11921498 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg metadoxine (given intravenously) added to standard treatment
Number of subjects: 52
Study 11921498 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 52
Study 10619926 — intervention group
Group type: EXPERIMENTAL
Intervention: Human serum protein (HSP) 5%
Number of subjects: 24
Study 10619926 — intervention group
Group type: COMPARATOR
Intervention: Human albumin (HA) 5%
Number of subjects: 24
Study 9055913 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth-promoting treatment
Number of subjects: 28
Study 2031602 — intervention group
Group type: EXPERIMENTAL
Intervention: Artificial surfactant (ALEC)
Number of subjects: 294
Study 7033015 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen 100 mg suppository
Number of subjects: 40
Study 7033015 — intervention group
Group type: COMPARATOR
Intervention: Indomethacin 100 mg suppository
Number of subjects: 40
Study 31174888 — intervention group
Group type: EXPERIMENTAL
Intervention: Socially Supportive Activities Program (SSAP)
Number of subjects: 68
Study 31174888 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 68
Study 28166787 — intervention group
Group type: EXPERIMENTAL
Intervention: Protected Mealtimes intervention
Number of subjects: 149
Study 28166787 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 149
Study 26458872 — intervention group
Group type: EXPERIMENTAL
Intervention: unguided web‐based self‐help for problematic drinking
Number of subjects: 528
Study 26458872 — intervention group
Group type: EXPERIMENTAL
Intervention: adherence‐focused guided self‐help
Number of subjects: 528
Study 26458872 — intervention group
Group type: COMPARATOR
Intervention: waiting list control
Number of subjects: 528
Study 22419369 — intervention group
Group type: EXPERIMENTAL
Intervention: rhPTH (1‐34) (20 μg, once-daily subcutaneous injection)
Number of subjects: 124
Study 22419369 — intervention group
Group type: COMPARATOR
Intervention: elcatonin (200 U, once-weekly intramuscular injection)
Number of subjects: 124
Study 21273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 0.6 mg
Number of subjects: 37
Study 21273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2 mg
Number of subjects: 37
Study 21273395 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 37